CN102106974B - 偏瘫康复口服液 - Google Patents
偏瘫康复口服液 Download PDFInfo
- Publication number
- CN102106974B CN102106974B CN2011100423623A CN201110042362A CN102106974B CN 102106974 B CN102106974 B CN 102106974B CN 2011100423623 A CN2011100423623 A CN 2011100423623A CN 201110042362 A CN201110042362 A CN 201110042362A CN 102106974 B CN102106974 B CN 102106974B
- Authority
- CN
- China
- Prior art keywords
- radix
- hemiplegia
- oral liquid
- hours
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010019468 Hemiplegia Diseases 0.000 title claims abstract description 52
- 239000007788 liquid Substances 0.000 title claims abstract description 30
- 230000035876 healing Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 4
- 241000305492 Gastrodia Species 0.000 claims abstract description 3
- 241000219780 Pueraria Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 15
- 241000180649 Panax notoginseng Species 0.000 claims description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 14
- 241000237636 Pheretima Species 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 231100000956 nontoxicity Toxicity 0.000 claims description 3
- 239000008020 pharmaceutical preservative Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 38
- 210000004369 blood Anatomy 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 22
- 208000006011 Stroke Diseases 0.000 abstract description 21
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 18
- 230000017531 blood circulation Effects 0.000 abstract description 17
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 10
- 230000008506 pathogenesis Effects 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 241000213006 Angelica dahurica Species 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000270273 Ptyas dhumnades Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 241000489492 Arisaema Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 241000237903 Hirudo Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YQNGUUQYDSHYMO-MVAXXSNXSA-N 5-hydroxy-4-[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexa-3,5-diene-1,2-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(C(=O)C=C1O)=O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 YQNGUUQYDSHYMO-MVAXXSNXSA-N 0.000 description 1
- 241000271039 Agkistrodon Species 0.000 description 1
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- SBAFZBVZGFUKPK-MVAXXSNXSA-N Carthamone Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(C(O)=CC1=O)=O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 SBAFZBVZGFUKPK-MVAXXSNXSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 241001593750 Turcica Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- -1 saffloside Chemical compound 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Abstract
本发明涉及中医药制品中的一种治疗偏瘫的口服液,所用原料的重量份配比为:生黄芪90-180、当归3-15、赤芍3-10、地龙3-10、川芎3-10、桃仁3-10、红花3-10、葛根5-15、三七2-5、天麻8-15、乌梢蛇5-20。本发明针对偏瘫的病因病机而设计,配伍科学、主次清楚,能多方面兼顾,具有补气血、活血通络、止血、祛风等功效。它的原材料易找,制备工艺简单,服用方便,无毒副作用,康复效果好。经多年在临床上对863例脑血管意外(中风)引起偏瘫患者实施试服治疗,全部接受试服治疗的患者都有显著疗效,其中820例患者达临床康复,其治疗有效率达100%,治愈率95%。
Description
技术领域
本发明属于中医药配制品,特别涉及一种治疗脑血管意外(中风)引起的偏瘫的中成药。
背景技术
偏瘫属中医学的痿症(中风后遗症),是脑血管意外(中风)后引起的同侧上、下肢肢体瘫痪。症见半身不遂,肌肉、关节痿缩,肢体麻木、乏力,语言不利,感觉障碍,口眼斜 等。病机是:脑血管意外(中风)后,人体内出现气血亏虚,气滞血瘀,经络阻塞,气血运行不畅,筋脉、肌肉、关节失养,虚风内动等引起偏瘫。偏瘫给病人带来极大痛苦,常规治疗难以达到理想效果,中医疗法是针对偏瘫的病因病机,确定最佳治疗方案。其治疗原则为:补气血,活血通络,止血、祛风。在现有技术中,有一件发明名称为《治疗中风偏瘫的中药及其制造方法》的CN1415360 A于2003年5月7日公开,它由水蛭、川芎、桃仁、葛根、地龙、,蕲蛇、红花、川牛膝、三七、黄芪、赤芍组成。在该技术方案中,活血化瘀、通络药物偏重,适用于脑血栓、脑梗塞引起的偏瘫,不适用于脑出血性引起的偏瘫,水蛭破血逐瘀、脑出血性引起的偏瘫禁用;其二,偏瘫病久,久病必气血虚,本方案中调补气血的药物偏轻,只有黄芪一味补气药且剂量偏轻,无补血药物。还有一件发明名称为《一种治疗偏瘫的药物》的CN1736464A 于2006年2月22日公开,它由丽参、当归、川芎、白芍、红花、桃仁、防风、丹参、地龙、牛膝、桂枝、菊花、胆南星、白附子、薄荷、黄芪、蜈蚣、首乌、天麻、还魂丹、赭石、双勾等22味药物组成。在该技术方案中,防风、桂枝、菊花、双勾为祛风发散药物,偏瘫病久体虚,不宜使用发散药物,与治风先治血的理论不相符;胆南星、白附子为祛痰药物,对偏瘫无痰者、不宜使用,缺乏止血方面的药物,不适用于脑出血性引起的偏瘫。
发明内容
针对现有技术存在的缺陷,本发明拟根据偏瘫的病因病机而设计,提供一种治疗偏瘫的口服液,使之配伍科学,主次清楚,多方面兼顾,用于治疗脑血管意外(中风)引起的偏瘫,使之具有补气血,活血通络、止血、祛风的功效,并且具有使用方便、见效快、疗效显著、无副作用,有效率高的特点。
采取以下技术方案来实现本发明的上述目的。
一种治疗偏瘫的口服液所用原料及它们的重量份配比为:
生黄芪90-180 当归3-15 赤芍3-10 地龙3-10 川芎3-10 桃 仁 3-10 红花 3-10 葛根 5-15 三七2-5 天麻 8-15 乌梢蛇 5-20。
本发明治疗偏瘫的口服液所用原料的最佳重量份配比是:
生黄芪120 当归6 赤芍5 地龙3 川芎3 桃 仁 3 红花3 葛根10 三七 3 天麻10 乌梢蛇 10。
将上述各原料组份制成本发明治疗偏瘫的口服液的制备方法是:
按所用原料的重量份配比量,先将黄芪、当归、赤芍、地龙、川芎 、桃仁、红花、葛根、乌梢蛇9味药物加水煎煮三次,第一、二次各2小时,第三次1小时,合并煎液,浓缩至密度为1.014-1.029g∕cm3,静置至少24小时后过滤,滤液备用;将三七和天麻分别粉碎成细粉,分别用重量浓度为75%的乙醇按1:10重量比回流提取三次,每次2小时,合并提取液,过滤,回收乙醇后的滤液备用;再将三七和天麻的药渣混合加水煎煮三次,第一次、二次各2小时,第三次1小时,合并煎液,浓缩至密度为1.014-1.029g∕cm3,静置至少24小时后过滤,滤液与第一步所制的滤液和第二步所制的滤液合并,添加微量药品防腐剂后冷藏48小时,过滤,灭菌,灌装,即得产品。
本发明治疗偏瘫的口服液的配伍意义:脑血管意外(中风)之后,正气亏虚,气虚血瘀,脉络瘀阻,导致筋脉、肌肉、关节失去濡养而见偏瘫症状。以气血虚为本,血瘀为标。治当补气血为主,活血通络、止血、祛风为辅。重用生黄芪补益元气,意在气旺则血行,瘀去络通为君药;当归补血、活血、通络而不伤血,助黄芪增强补气血之功,意在血能生气为臣药;赤芍、川芎、桃仁、红花活血祛瘀;地龙、乌梢蛇为血肉有情之品,通经活络、祛风,力专善走,周行全身,以行药力,通利肢节;三七化瘀生新、止血而不留瘀,化瘀而不伤正;天麻祛风通络为佐药,葛根生津解肌为使药。配伍特点是重用黄芪配当归以补气血。重用黄芪配少量活血药物,使气血旺、血得行以治本。祛瘀通络、祛风药以治标,止血药以防止继发性出血,标本兼顾。全方治疗脑血管意外(中风)所引起的偏瘫有疗效显著。
本发明治疗偏瘫的口服液药理分析:生黄芪含苷类、多糖、黄酮、氨基酸、微量元素等成份,能促使机体代谢、抗疲劳,提高抗病力,延长寿命,保护心脑血管,抗衰老,扩张冠状脉和外周血管,减少血栓形成,促进血清更新,有健脾补气功效。当归含有β-蒎烯、α-蒎烯、有机酸、糖类、维生素、氨基酸等成份,显著扩张冠状动脉,增加冠脉血流量,能促进血红蛋白及红细胞的生成,有补血活血功效。赤芍含有芍药苷,没食子鞋质,苯甲酸,挥发油等成份,能扩张冠状动脉,增加冠脉血流量;芍药苷及衍生物有抑制血小板聚集,延长体外血栓形成时间,减轻血栓干重等作用,有散瘀止痛,凉血功效。地龙含有多种氨基酸、微量元素、有机酸、蚯蚓素、酶类等成份,有拮抗组织胺、纤溶和抗凝,增强免疫、利尿,兴奋平滑肌等作用,有通络、定悸、利尿的功效。川芎含有生物碱(川芎嗪),挥发油,酚类物质及维生素A、叶酸、甾醇等成份,能扩张冠状动脉,增加冠脉血流量,川芎嗪可扩张脑血管,降低血管阻力,显著增加脑及肢体血流量、改善微循环,抑制血小板凝集、预防血栓形成,有活血行气、祛风止痛功效。桃仁含有苦杏仁苷,挥发油、脂肪油、甘油脂、少量亚油酸等成份,能明显增加脑血流量,降低血管阻力,延长出血和凝血时间,对体外血栓有抑制作用,有纤维促进作用,润肠排便等作用,有活血化瘀、润肠通便的功效。红花含有红花醌苷、红花苷、红花黄色素和红花油等成份,能降低冠脉阻力,增加冠脉流量,扩张周围血管,抑制血小板聚集,增强纤维蛋白溶解,降低全血粘度,对缺血、缺氧性脑病有保护作用,对中枢神经有镇痛、抗惊厥作用,具有活血通络,祛瘀止痛的功效。葛根含有黄酮类物质,葛根素、葛根醇、淀粉等成份,扩张冠脉血管和脑血管,增加冠脉血流量和脑血流量,降低心肌耗氧量,增加氧供应,直接扩张血管,使外周阻力降低,改善微循环,抑制血小板凝集,有解肌、生津之功效。三七含有皂苷、黄酮苷、氨基酸等成份,能缩短出血和凝血时间,具有抗血小板聚集及溶栓作用,能促进多功能造血干细胞的增殖,扩张脑血管,增加脑血流量,提高机体免疫功能,有化瘀活血、止血、定痛的功效。乌梢蛇含有17种氨基酸、果糖、二磷酸酶、原肌球蛋白等成份,有抗炎、镇静、镇痛等作用,具有祛风通络、止痛的功效。天麻含有天麻苷,天麻苷元,甾旨醇、胡萝卜苷、柠檬酸、琥珀酸和蔗糖、纤维素A、多种氨基酸、微量生物碱及多种微量元素等成份,有降低外周血管、脑血管、冠状血管阻力,有熄风止痉、祛风通络、平抑肝阳的功效。
本发明的治疗偏瘫的口服液,全方是针对脑血管意外(中风)之后,正气亏虚、气虚血瘀、脉络瘀阻的病因病机而设计的,配伍科学、主次清楚。多方面兼顾,具有补气血、活血通络、止血、祛风等功效。经多年在临床上对863例脑血管意外(中风)引起偏瘫患者实施试服治疗,全部接受试服治疗的患者都有显著疗效,其中820例患者达临床康复,其治疗有效率达100%,治愈率95%。它的原材料易找,制备工艺简单,服用方便,无毒副作用,康复效果好。
具体实施方案
下面举一个组方的具体制造实例和多个典型病例,来进一步说明本发明的治疗偏瘫的口服液及其它的治疗效果。需要指出的是,本发明的治疗偏瘫的口服液绝不局限所举实例和典型病例。
一、制造实例
1)配方:生黄芪120kg、当归6kg、赤芍5kg、地龙3kg、川芎3kg 、桃仁3kg、红花3kg、葛根10kg、三七3kg、乌梢蛇10kg、天麻10kg;
2)制备方法:按所用原料的重量配比量,先将黄芪、当归、赤芍、地龙、川芎 、桃仁、红花、葛根、乌梢蛇9味药物加水煎煮三次,第一、二次各2小时,第三次1小时,合并煎液,浓缩至密度为1.014-1.029g∕cm3,静置至少24小时后过滤,滤液备用;将三七和天麻分别粉碎成细粉,分别用重量浓度为75%的乙醇按1:10重量比回流提取三次,每次2小时,合并提取液,过滤,回收乙醇后的滤液备用;再将三七和天麻的药渣混合加水煎煮三次,第一次、二次各2小时,第三次1小时,合并煎液,浓缩至密度为1.014-1.029g∕cm3,静置至少24小时后过滤,滤液与第一步所制的滤液和第二步所制的滤液合并,添加微量药品防腐剂后冷藏48小时,过滤,灭菌,灌装,即得产品。
二、典型病例
病例1:熊某某,女,57岁,84岁,突然头昏、四肢无力,继而失语,口眼斜,大小便失禁,经某三甲医院诊断为急性脑溢血,经抢救后,出现语言不利,左侧上下肢无力,感觉障碍等。诊断为脑血管意外引起的偏瘫,内服治疗偏瘫的口服液3个月,偏瘫症状减轻,内服治疗偏瘫的口服液6个月,生活能自理,继续服用治疗偏瘫的口服液1年,达临床痊愈;
病例2:曾某某,男,69岁,患脑血栓经某三甲医院手术后出现左侧上、下肢偏瘫,语言不利,诊断为脑血栓引起的偏瘫。内服治疗偏瘫的口服液3个月,偏瘫症状减轻,内服治疗偏瘫的口服液6个月,生活能自理,继续服用治疗偏瘫的口服液1年,达临床痊愈;
病例3:王某某,男,73岁,患急性脑溢血,经某医院抢救后住院治疗三个月出院,症见右侧上下肢偏瘫,诊断为脑溢血引起的偏瘫,内服治疗偏瘫的口服液6个月,偏瘫症状减轻,继续服用治疗偏瘫的口服液1年,达到临床痊愈;
病例4:李某某,男,79岁,患者头昏头胀、时轻时重,偶见神志恍惚,见左上、下肢麻木、震颤、轻度乏力,诊断为脑萎缩,内服治疗偏瘫的口服液6个月,临床症状减轻,继续服用治疗偏瘫的口服液1年,达到临床痊愈。
Claims (2)
1.一种治疗偏瘫的口服液,其特征在于:
1)所用原料及它们的重量份配比为,
生黄芪90-180 当归3-15 赤芍3-10 地龙3-10 川芎3-10 桃 仁 3-10 红花 3-10 葛根 5-15 三七2-5 天麻 8-15 乌梢蛇 5-20;
2)它的制备方法是,按所用原料的重量份配比量,先将黄芪、当归、赤芍、地龙、川芎 、桃仁、红花、葛根、乌梢蛇9味药物加水煎煮三次,第一、二次各2小时,第三次1小时,合并煎液,浓缩至密度为1.014-1.029g∕cm3,静置至少24小时后过滤,滤液备用;将三七和天麻分别粉碎成细粉,分别用重量浓度为75%的乙醇按1:10重量比回流提取三次,每次2小时,合并提取液,过滤,回收乙醇后的滤液备用;再将三七和天麻的药渣混合加水煎煮三次,第一次、二次各2小时,第三次1小时,合并煎液,浓缩至密度为1.014-1.029g∕cm3,静置至少24小时后过滤,滤液与第一步所制的滤液和第二步所制的滤液合并,添加微量药品防腐剂后冷藏48小时,过滤,灭菌,灌装,即得产品。
2. 按照权利要求1所述的治疗偏瘫的口服液,其特征在于所用原料的重量份配比为:
生黄芪120 当归6 赤芍5 地龙3 川芎3 桃 仁 3 红花3 葛根10 三七 3 天麻10 乌梢蛇 10。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100423623A CN102106974B (zh) | 2011-02-22 | 2011-02-22 | 偏瘫康复口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100423623A CN102106974B (zh) | 2011-02-22 | 2011-02-22 | 偏瘫康复口服液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102106974A CN102106974A (zh) | 2011-06-29 |
CN102106974B true CN102106974B (zh) | 2012-05-30 |
Family
ID=44171330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100423623A Expired - Fee Related CN102106974B (zh) | 2011-02-22 | 2011-02-22 | 偏瘫康复口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102106974B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656237A (zh) * | 2013-12-12 | 2014-03-26 | 陈树亮 | 一种天赤痛经散及其制备方法 |
CN104013832A (zh) * | 2014-06-05 | 2014-09-03 | 湖州康企药业有限公司 | 一种治疗偏瘫的药物 |
CN104001068A (zh) * | 2014-06-11 | 2014-08-27 | 刘光辉 | 一种治疗中风后遗症的中药组合物 |
CN104644806A (zh) * | 2015-01-26 | 2015-05-27 | 曾翠芸 | 一种预防中风的药物组合物 |
CN105288241A (zh) * | 2015-11-30 | 2016-02-03 | 闻喜县红十字会心脑血管病专科医院 | 一种治疗中风、气虚血瘀的中药及其制备方法 |
CN111617175A (zh) * | 2020-06-22 | 2020-09-04 | 向美润 | 一种治疗肢体关节疼痛的中药组合物、制备方法及应用 |
CN111888392A (zh) * | 2020-08-27 | 2020-11-06 | 御元堂药业股份有限公司 | 一种治疗冠心病、脑梗、动脉硬化及预防中风的中药组方 |
CN113304204A (zh) * | 2021-04-12 | 2021-08-27 | 陆州宏 | 一种治疗中风偏瘫的中药及其制作方法 |
CN115969907A (zh) * | 2022-12-30 | 2023-04-18 | 哈尔滨市龙生北药生物工程股份有限公司 | 蛭龙血通胶囊及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721664A (zh) * | 2008-11-04 | 2010-06-09 | 王生 | 一种治疗中风偏瘫及全身瘫痪的中药 |
-
2011
- 2011-02-22 CN CN2011100423623A patent/CN102106974B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721664A (zh) * | 2008-11-04 | 2010-06-09 | 王生 | 一种治疗中风偏瘫及全身瘫痪的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN102106974A (zh) | 2011-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102106974B (zh) | 偏瘫康复口服液 | |
CN1302805C (zh) | 一种防治脑中风的中成药 | |
CN103071048B (zh) | 一种治疗阿尔茨海默病的中药组合物及其制备方法 | |
CN101507765B (zh) | 一种用于治疗心脑血管疾病及其后遗症的药物及其制备方法 | |
CN102512632B (zh) | 一种治疗月经不调的中药组合物 | |
CN102940785B (zh) | 一种治疗眩晕症的中药组合物 | |
CN1058893C (zh) | 治疗妇女痛经的药物及其制备方法 | |
CN102579610B (zh) | 一种治疗脑出血的中药组合物及其制备方法 | |
CN105902793A (zh) | 一种治疗冠心病的中药 | |
CN102451449A (zh) | 温经散寒胶囊 | |
CN106938048A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN102114211B (zh) | 一种治疗肝炎的中草药 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102406769B (zh) | 一种治疗高血压、高血脂、动脉硬化、冠心病的中药制剂及其制备方法 | |
CN101239114A (zh) | 一种治疗肝郁脾虚泄泻的药物组合物及其制备方法 | |
CN102895352B (zh) | 药物组合物及其用途 | |
CN102895529A (zh) | 一种治疗中风的药物 | |
CN102397391A (zh) | 治疗高血压、高血脂、高粘血症的药物及其制备方法 | |
CN107334963A (zh) | 一种治疗肾病综合征的药剂及其制备方法 | |
CN101745084A (zh) | 用于中枢神经损伤康复治疗的中药制剂 | |
CN105343688A (zh) | 一种治疗心肌梗塞的药物组合物及其应用 | |
CN101049439A (zh) | 脑缺血康复合剂 | |
CN105832934A (zh) | 一种治疗高血压病的中药 | |
CN105456947A (zh) | 一种治疗股骨头缺血性坏死的药物组合物及其应用 | |
CN105726838A (zh) | 一种外用复方中药热敷布袋 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 |